Browsing by Author "Paydas, Semra"
Now showing items 1-4 of 4
-
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study
Yildiz, Birol; Kucukarda, Ahmet; Gokyer, Ali; Demiray, Atike Gokcen; Paydas, Semra; Aral, Ipek Pinar; Gumusay, Ozge (Imprimatur Publications, 2020)Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients. Methods: In our study, 612 seminomatous ... -
Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma
Paydas, Semra; Lacin, Sahin; Dogan, Mutlu; Barista, Ibrahim; Yildiz, Birol; Seydaoglu, Gulsah; Karadurmus, Nuri (Pergamon-Elsevier Science Ltd, 2021)The aim of this study is to determine the power of he international prognostic scoring systems (IPS-7 and IPS-3) and to obtain indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) ... -
Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial
Demir, Atakan; Mandel, Nil Molinas; Paydas, Semra; Demir, Gökhan; Er, Özlem; Turhal, Nazım Serdal; Bavbek, Sevil; Eralp, Yeşim; Saip, Pınar Mualla; Güler, Emine Nilüfer; Aydıner, Adnan; Uluç, Başak Oyan; Kılıçkap, Sadettin; Üskent, Necdet; Karadurmuş, Nuri; Kaplan, Mehmet Ali; Yanmaz, Mustafa Teoman; Demir, Hacer; Alan, Özkan; Korkmaz, Taner; Olgun, Polat; Uysal, Özlem Sönmez; Altundağ, Kadri; Gündüz, Seyda; Günaldı, Meral; Sarı, Murat; Beypınar, İsmail; Başaran, Gül (Aves, 2020)Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite ... -
Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)
Icli, Fikri; Altundag, Kadri; Akbulut, Hakan; Paydas, Semra; Basaran, Gul; Saip, Pinar; Dogu, Gamze G. (Springer Japan Kk, 2015)Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer ...
